Positive Preclinical Data for Docetaxel ChemoSeed

596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.

CRISM Therapeutics Corporation

('CRISM', 'CRISM Therapeutics' or the 'Company')

Positive preclinical data for Docetaxel-ChemoSeed in prostate cancer model

CRISM Therapeutics (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, today is pleased to announce positive preclinical results for its Docetaxel-ChemoSeed implantable drug delivery technology, demonstrating significant anti-tumour activity, evidence of dose response, and a favourable tolerability profile compared to standard systemic docetaxel in a prostate cancer model.

Prostate cancer, the most prevalent cancer in men, is the second programme in CRISM's pipeline of product opportunities using the implantable ChemoSeed drug delivery platform. The Company's most advanced programme, Irinotecan-ChemoSeed in glioblastoma, remains on track for the first patients to be dosed in an open label Phase 2 clinical trial in H1 2026.

The study evaluated tumour growth and tolerability across multiple treatment groups, including untreated control, placebo, systemic docetaxel (standard of care), and varying dose levels of Docetaxel-ChemoSeed. Docetaxel-ChemoSeed demonstrated consistent anti-tumour activity, a clear dose-response relationship, and a favourable tolerability profile. Tumour volumes were reduced across multiple dose levels, with the most pronounced effect demonstrating a 58% reduction in tumour volume when compared to standard of care. A dose-dependent trend was evident for Docetaxel-ChemoSeed, supporting controlled drug delivery. Importantly, no adverse tolerability effects or early terminations were observed in any ChemoSeed-treated groups, with body weight remaining stable, whereas standard of care was associated with reduced tolerability and multiple terminations. These findings demonstrate that the sustained, localised delivery of docetaxel using CRISM's proprietary ChemoSeed drug delivery platform, substantially enhances the efficacy of docetaxel improving therapeutic outcomes while minimising systemic effects in the treatment of prostate cancer.

These results further validate the Company's strategy to develop a localised chemotherapy approach designed to overcome the limitations of systemic treatment.

Chris McConville, Chief Scientific Officer of CRISM Therapeutics, said: "The data clearly demonstrates that delivering chemotherapy locally and continuously, rather than intermittently and systemically, provides a much-needed improvement in therapeutic efficacy and tolerability. The combination of tumour control, dose response and favourable tolerability observed in this study is encouraging and underpins our confidence in the potential of this technology as a localised treatment option for prostate cancer. These findings strongly support the continued development of Docetaxel-ChemoSeed and represent a meaningful step toward clinical evaluation. We welcome discussions with potential partners and collaborators as we build momentum towards first-in-human clinical trials."

The Company's LEI is 213800XFW6MKVCHHPW88.